Safety profile and side effects When considering the safety profile and side effects of semaglutide and Zepbound, it is important to recognize the similarities and differences that exist between these two medications: Common side effects: Nausea Diarrhea Vomiting Constipation Indigestion Stomach pain Abdominal pain Severe side effects: Hypoglycemia (low blood sugar) Pancreatitis (inflammation of the pancreas) Severe allergic reactions Gallbladder problems Both semaglutide and Zepbound carry a boxed warning regarding the risk of thyroid C-cell tumors, an important consideration for patients with a history of thyroid cancer
It may also help down melanin production
The FDA noted that "CAPA CA 90 was initiated on April 9, 2024, for 731 Series Ventilators with MRI compatibility nonconformances, resulting in a Class I recall that was not initiated until April 30, 2024." The company's complaint analysis system failed to detect the pattern because complaints were coded as "User Errors," "No Fault Found," "No Product Returned," and "User Attempted Repairs." These ventilator failures "caused malfunctions and shutdowns that led to the stoppage of ventilatory support and the need for alternative means of ventilation." Even after closing the CAPA as effective in September 2024, Zoll received 6 complaints relating to the MRI compatibility issues from November 15, 2024, through January 16, 2025, after closure of the CAPA and no additional CAPAs have been initiated
Despite the body's natural production of glutathione, maintaining healthy levels can be challenging due to adverse environmental factors
The ones cited in every press release announcing this drug as a breakthrough
